SAN
DIEGO, June 10, 2022 /PRNewswire/ -- Kintara
Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a
biopharmaceutical company focused on the development of new solid
tumor cancer therapies, today announced that President and CEO
Robert E. Hoffman will present a
corporate overview at the JMP Securities Life Sciences
Conference. The conference is being held on June 15 – 16, 2022 at the Lotte New York Palace
Hotel.
Presentation
Date:
|
Thursday,
June 16, 2022
|
Time:
|
11:30am ET
|
Webcast
Link:
|
https://wswcom/webcast/jmp54/ktra/1682208
|
A live webcast of the presentation at the JMP Securities Life
Sciences Conference will be available on
https://ir.kintara.com/news-events. A replay of the
webcast will be available for 30 days after the date of the
presentation.
Mr. Hoffman will be available for one-on-one meetings with
registered attendees of the conference.
About Kintara
Located in San Diego,
California, Kintara is dedicated to the development of novel
cancer therapies for patients with unmet medical needs. Kintara is
developing two late-stage, Phase 3-ready therapeutics for clear
unmet medical needs with reduced risk development programs.
The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and
REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).
VAL-083 is a "first-in-class," small-molecule
chemotherapeutic with a novel mechanism of action that has
demonstrated clinical activity against a range of cancers,
including central nervous system, ovarian and other solid tumors
(e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical
trials sponsored by the National Cancer Institute (NCI). Based on
Kintara's internal research programs and these
prior NCI-sponsored clinical studies, Kintara is
currently advancing VAL-083 in the GBM AGILE study to support the
development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary, late-stage
photodynamic therapy platform that holds promise as a localized
cutaneous, or visceral, tumor treatment as well as in other
potential indications. REM-001 therapy has been previously
studied in four Phase 2/3 clinical trials in patients with CMBC who
had previously received chemotherapy and/or failed radiation
therapy. With clinical efficacy to date of 80% complete responses
of CMBC evaluable lesions, and with an existing robust safety
database of approximately 1,100 patients across multiple
indications, Kintara is advancing the REM-001 CMBC
program to late-stage pivotal testing.
For more information, please visit www.kintara.com or
follow us on Twitter
at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the GBM AGILE study. Any
forward-looking statements contained herein are based on current
expectations but are subject to a number of risks and
uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the impact
of the COVID-19 pandemic on the Company's operations and clinical
trials; the Company's ability to develop, market and sell products
based on its technology; the expected benefits and efficacy of the
Company's products and technology; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors
are identified and described in more detail in the Company's
filings with the SEC, including the Company's Annual Report on Form
10-K for the year ended June 30,
2021, the Company's Quarterly Reports on Form 10-Q, and the
Company's Current Reports on Form 8-K.
CONTACTS
Investors:
CORE IR
516-222-2560
ir@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-jmp-securities-life-sciences-conference-301565592.html
SOURCE Kintara Therapeutics